Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Celldex Therapeutics
Biotech
Celldex ends skin disease program after failing phase 2 test
A phase 2 study of Celldex’s barzolvolimab in a skin disease missed its primary endpoint, driving the biotech to end development in the indication.
Nick Paul Taylor
Jul 22, 2026 6:00am
Ovid eyes next chapter with CEO transition—Chutes & Ladders
Nov 14, 2025 8:30am
Celldex ends esophageal program despite hitting primary endpoint
Aug 20, 2025 6:42am
Celldex drops phase 1 tumor bispecific to focus on inflammation
Nov 7, 2024 7:25am
Celldex anti-cKIT antibody reduces hives in another phase 2 test
Jul 30, 2024 5:50am
Celldex laces up next to Big Pharmas with chronic hive drug
Nov 6, 2023 10:17am
